Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Medtronic
McKesson
Colorcon
QuintilesIMS
Express Scripts
Novartis
US Department of Justice
Argus Health

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,169,791

« Back to Dashboard

Which drugs does patent 7,169,791 protect, and when does it expire?

Patent 7,169,791 protects TASIGNA and is included in one NDA.

This patent has fifty-five patent family members in thirty countries.
Summary for Patent: 7,169,791
Title:Inhibitors of tyrosine kinases
Abstract:The invention relates to compounds of formula ##STR00001## wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
Inventor(s): Breitenstein; Werner (Basel, CH), Furet; Pascal (Thann, FR), Jacob; Sandra (Rantzwiller, FR), Manley; Paul William (Arlesheim, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/520,359
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,169,791

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y Y A METHOD FOR THE TREATMENT OF LEUKEMIAS ➤ Subscribe
Novartis TASIGNA nilotinib hydrochloride monohydrate CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y A METHOD FOR THE TREATMENT OF LEUKEMIAS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,169,791

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0215676.8Jul 05, 2002
United Kingdom0229893.3Dec 20, 2002
PCT Information
PCT FiledJuly 04, 2003PCT Application Number:PCT/EP03/07198
PCT Publication Date:January 15, 2004PCT Publication Number: WO20/04/005281

Non-Orange Book US Patents Family Members for Patent 7,169,791

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,566 Inhibitors of tyrosine kinases ➤ Subscribe
7,956,053 Inhibitors of tyrosine kinases ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,169,791

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2004005281 ➤ Subscribe
Taiwan I313603 ➤ Subscribe
Taiwan 200403060 ➤ Subscribe
Slovenia 1532138 ➤ Subscribe
Russian Federation 2445309 ➤ Subscribe
Russian Federation 2348627 ➤ Subscribe
Russian Federation 2008137927 ➤ Subscribe
Russian Federation 2005102917 ➤ Subscribe
Portugal 1532138 ➤ Subscribe
Portugal 2357182 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Express Scripts
Colorcon
Teva
Cantor Fitzgerald
Covington
Johnson and Johnson
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot